Two Sigma Investments’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,197
Closed -$23K 3096
2022
Q1
$23K Sell
1,197
-1,269
-51% -$28.3K ﹤0.01% 2523
2021
Q4
$88K Buy
+2,466
New +$140K ﹤0.01% 4080
2021
Q3
Sell
-2,522
Closed -$352K 4879
2021
Q2
$352K Buy
+2,522
New +$443K ﹤0.01% 3376

Other funds holding SGTX

Two Sigma Investments's SGTX Position: Q2 2022 in Review

Two Sigma Investments sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 1,197 shares — an estimated $23K sold.

Two Sigma Investments first reported a position in SGTX in Q2 2021 and held it in 3 quarters. The position peaked at $352K in Q2 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • Two Sigma Investments reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Investments sold 1,197 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $23K.
  • Two Sigma Investments first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Two Sigma Investments's Sigilon Therapeutics, Inc. Common Stock position peaked at $352K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.